Targeted therapy of cancer using diphtheria toxin-derived immunotoxins

Drug Discovery Today

Volumn 13, Issue 17-18, 2008, Pages 807-815

  Potala, Sirisha ^a   Sahoo, Sanjeeb K ^b   Verma, Rama S ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 50 4798; CYTOKINE RECEPTOR AGONIST; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; GAMMA INTERFERON; GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIGAND; LYMPHOTOXIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CELL; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; CELL SURFACE; CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; MOLECULAR RECOGNITION; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; DIPHTHERIA TOXIN; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 51249107097     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.06.017     Document Type: Review

References (84)

1. Marchini S., et al. New molecules and strategies in the field of anticancer agents. Curr. Med. Chem.-Anticancer Agents 4 (2004) 247-262
2. Rew D.A., and Wilson G.D. Eur. J. Surg. Oncol. 26 (2000) 227-238
3. Benedict W.F., et al. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test. Cancer Res. 37 (1977) 2209-2213
4. Khandare J.J., and Minko T. Antibodies and peptides in cancer therapy. Crit. Rev. Ther. Drug Carrier Syst. 23 (2006) 401-435
5. Fuchs H., et al. A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J. Control Release 117 (2007) 342-350
6. Schaefer N.G., et al. Potential use of humanized antibodies in the treatment of breast cancer. Expert Rev. Anticancer Ther. 6 (2006) 1065-1074
7. Zhang H., et al. Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line. Cancer. Biother. Radiopharm. 21 (2006) 321-332
8. Kramer K., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J. Clin. Oncol. 25 (2007) 5465-5470
9. Zumkeller W., and Schofield P.N. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res. 15 (1995) 343-348
10. Smith K.A. Lowest dose interleukin-2 immunotherapy. Blood 81 (1993) 1414-1423
11. Lores B., et al. Lymph nodes and human tumors (review). Int. J. Mol. Med. 4 (1998) 729-733
12. Elisabeth S., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187 (1998) 1349-1354
13. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
14. Lissoni P. Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J. Sci. Am. (1997) S115-S120
15. Deehan D.J., et al. In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br. J. Cancer. 69 (1994) 1130-1135
16. Jin P., et al. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit. Rev. Immunol. 27 (2007) 437-448
17. Wang H.M., and Smith K.A. The interleukin 2 receptor: Functional consequences of its bimolecular structure. J. Exp. Med. 166 (1987) 1055-1069
18. Teshigawara K., et al. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J. Exp. Med. 165 (1987) 223-238
19. Nelson B.H., et al. Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation of special interest. Nature 369 (1994) 333-336
20. Church A.C. Clinical advances in therapies targeting the interleukin-2 receptor. Q. J. Med. 96 (2003) 91-102
21. Streck C.J., et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-β. Cancer Gene Ther. 13 (2006) 99-106
22. Gavin P.D., et al. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006) 836-848
23. FitzGerald D., and Pastan I. Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst. 81 (1989) 1455-1463
24. Robert J.K., and Ira P. Immunotoxins for targeted cancer therapy. Adv. Drug Deliv. Rev. 31 (1998) 53-88
25. Rathore D., and Batra J.K. Construction, expression and characterization of chimeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action. Biochem. J. 324 (1997) 815-822
26. Avila A.D., et al. Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin. Biol. Res. 40 (2007) 173-183
27. Rosenberg S.A., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210 (1989) 474-484
28. Brittenden J., et al. Natural killer cells and cancer. Cancer 77 (1996) 1226-1243
29. Rosenberg S.A., and Mule J.J. Immunotherapy of cancer with lymphokine- activated killer cells and recombinant interleukin-2. Surgery 98 (1985) 437-444
30. Kiselevskii M.V. Adoptive immunotherapy in malignant tumors. Vestn. Ross Akad. Med. Nauk. 1 (2003) 40-44
31. Queen C., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U.S.A 86 (1989) 10029-10033
32. Waldmann T.A., and Morris J.C. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv. Immunol. 90 (2006) 83-131
33. Pross H.F., and Lotzova E. Role of natural killer cells in cancer. Nat. Immun. 12 (1993) 279-292
34. Francine M.F. Interleuki-2 fusion toxin: Targeted therapy for Cutaneous T Cell Lymphoma. Ann. N Y Acad Sci 941 (2001) 166-176 IL-2
35. 389IL-2 (ONTAK) fusion protein therapy of chronic lymphocytic leukemia. Expert Opin. Boil. Ther. 3 (2003) 179-186
36. Claudio D.P., et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin. Cancer Res. 9 (2003) 2837-2848
37. Philip D.B., et al. New cancer related mutations found in breast and colon cancers. Adv. Targ. Cancer Ther. (2006) 4
38. Deborah A.T., et al. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng. Des. Select. 17 (2004) 157-164
39. Brad J.S., et al. Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv. Clin. Cancer Res. 13 (2007) 3058-3067
40. Jianhua R., et al. Interaction of diphtheria toxin T domain with molten globule like proteins and its implications for translocations. Science (1999) 284
41. Seunghyon C., et al. The crystal structure of diphtheria toxin. Nature (1992) 357
42. Brain G., et al. ADP ribosylation of elongation factor 2 by diphtheria toxin. J. Biol. Chem. 225 (1980) 10717-10720
43. Shihui L., et al. Identification of proteins required for biosynthesis of diphthamide, the target of bacterial ADP ribosylating toxins on translation elongation factor 2. Mol. Cell. Biol. (2004) 9487-9497
44. Arthur E.F., et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr. Cancer Drug Targets 2 (2002) 19-36
45. Tagg J.R., et al. Bacteriocins of gram-positive bacteria. Bacteriol. Rev. 40 (1976) 722-756
46. 2+-dependent DNA-binding repressor, DtoxR, in Corynebacterium diphtheriae. Infect Immun. 57 (1989) 3221-3225
47. Aruni D.Z., et al. Molecular characterization of diphtheria toxin repressor (dtxR) genes present in nontoxigenic Corynebacterium diphtheriae strains isolated in the United Kingdom. J. Clin. Microbiol. 43 (2005) 223-228
48. Hong Y.H., et al. The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389-IL-2. Protein Eng. 11 (1998) 812-817
49. Bennett M.J., and Eisenberg D. Refined structure of monomeric diphtheria toxin at 2.3 Å resolution. Protein Sci. 3 (1994) 1464-1475
50. Bennett M.J., et al. Defined structure of dimeric diphtheria toxin at 2.0 Å resolution. Protein Sci. 3 (1994) 1444-1463
51. Frankel A.E., et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr. Cancer Drug Targets 2 (2002) 19-36
52. Vanderspek J.C., et al. DAB389 interleukin-2 receptor binding domain mutations. Cytotoxic probes for studies of ligand-receptor interactions. J. Biol. Chem. 271 (1996) 12145-12149
53. Bi-yu L., and Ramakrishnan S. Recombinant hybrid toxin with dual enzymatic activities. J. Biol. Chem. 269 (1994) 2652-2658
54. 486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 265 (1990) 11885-11889
55. Greenfield L., et al. Mutation in diphtheria toxin seprate binding from a entry and amplify immunotoxin selectivity. Science 238 (1987) 536-539
56. Madeleine D., et al. DAB IL2 diphtheria fusion toxin produces clinical responses in tumor stage Cutaneous T Cell Lymphoma. Am. J. Hematol. 58 (1998) 87-90
57. Lemaistre C.F., et al. Phase I clinical trail of a ligand fusion protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 91 (1998) 399-405
58. Nicholas J., et al. Interleukins-2 fusion protein: An investigational therapy for interleukins-2 receptor expressing malignancies. Eur. J. Cancer 33 (1997) S34-S36
59. Chang T., et al. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate. J. Biol. Chem. 252 (1977) 1515-1522
60. Neville D.M., et al. Enhancement of immunotoxins efficacy by acid cleavable cross linking agents utilizing diphtheria toxin and toxin mutants. J. Biol. Chem. 264 (1989) 14653-14661
61. Jeffery O., et al. Expression and purification of the recombinant diphtheria fusion toxin DT IL3 for phase I clinical trials. Protein Expr. Purif. 33 (2004) 123-133
62. Liger D., et al. Characterization and receptor specific toxicity of two diphtheria toxin related intrleukin3 fusion proteins DAB-mIL-3 and DAB -(gly ser) -mIL-3. FEBS Lett. 406 (1997) 157-161
63. Frankel A.E., et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 13 (2000) 575-581
64. Kim K., et al. Immunotoxins therapy for primary malignant brain tumors. Int. Congr. Ser. 1247 (2002) 185-197
65. Thamm D.H. Interaction between radiation therapy and immunotherapy: the best of two worlds?. Vet. Comp. Oncol. 4 (2006) 189-197
66. Younes E., et al. Radiation-induced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy. J. Urol. 153 (1995) 2029-2033
67. Gottlieb A.B., and Bos J.D. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol. 105 (2000) 105-116
68. Gottileb S.L., et al. Response of psoriasis to a lymphocyte selective toxin (DAB IL-2) suggests a primary immune, but not keratinocyte, pathogenesis basis. Nat. Med. 1 (1995) 442-447
69. Woodworth T.G. Early clinical studies of IL-2 fusion toxin in patients with severe rheumatoid arthritis and recent onset insulin dependent diabetes mellitus. Clin. Exp. Rheumatol. 11 (1993) S177-S180
70. Nakamura S., et al. A new mouse model for renal lesions produced by intravenous injection of diphtheria toxin A chain expression plasmid. BMC Nephrol. 22 (2004) pp. 4, 5
71. Liu T.F., et al. Diphtheria toxin fused to variant interleukins-3 provides enhanced binding to the interleukins-3 receptor and more potent leukemia call cytotoxicity. Exp. Haematol. 32 (2004) 277-281
72. Gorgun G., and Foss F. RXR-selective retinoid, bexarotene (targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic leukemia (CLL) cells to Denileukin Diftitox (ONTAK). Blood 98 (2001) 150a
73. Shao R.H., et al. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk. Res. 26 (2002) 1077-1083
74. Conley B.A., et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res. 3 (1998) 629-634
75. Gorgun G., and Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood (2002) 100
76. Sidell N., et al. Retinoid regulation of interleukin-2 receptors on human T cells. Cell. Immunol. 179 (1997) 116-125
77. Gorgun G., et al. Enhanced cytotoxicity to DAB IL-2 (ONTAK) in human T cell lines by retinoic acid. Blood 94 (1999) 281a
78. Olsen E., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19 (2001) 376-388
79. Siegall C.B., et al. Prevention of immunotoxin-mediated immunogenicity by blockade of CD28-B7 mediated co-stimulation using CTLA4-Ig. J. Immunol. 159 (1997) 5168-5173
80. Tsutsumi Y., et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Sci. Acad. U.S.A. 97 (2000) 8548-8553
81. Frankel A.E., et al. Clinical trials of targeted toxins. Semin. Cancer Biol. 6 (1995) 307-317
82. Frankel A.E. Reducing the immune response to immunotoxin. Clin. Cancer Res. 10 (2004) 13-15
83. Steppan S., et al. Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J. Interferon Cytokine Res. 26 (2006) 171-178
84. Hu P., et al. Generation of low toxicity interleukin 2 fusion proteins devoid of vasopermeability activity. Blood 101 (2003) 4853-4861